Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses this phase 3 trial has shown improved overall survival and toxicity profile has been stable with prolonged exposure to drugs at the 2017 American Society of Hematology.
This Phase 3 Trial has Shown Improved Overall Survival – Toxicity Profile has been stable with prolonged exposure to drugs
